Dr. Elianne Vrijlandt has received consortium funding for her role in a consortium investigating supplemental oxygen strategies after the neonatal intensive care period in children with bronchopulmonary dysplasia (BPD). The other principal investigators in the consortium are Mariëlle Pijnenburg (Sophia KZ/ Erasmus MC) and Anton van Kaam (Emma KZ/ AMC).
Every year in the Netherlands, 500 preterm born children develop bronchopulmonary dysplasia (BPD), a chronic lung disease with life-long sequelae. The main treatment of BPD is supplemental oxygen. However, no study has ever examined the optimal oxygen saturation (SpO2) target in children with established BPD, while both too little and too much oxygen may lead to serious adverse events. International guidelines, based on expert opinion only, recommend a lower limit ranging between 93 and 95%, while limits of 90% are considered usual care in most Dutch neonatal units and regional hospitals.
The primary objective of this study is to investigate if targeting a higher SpO2 (i.e. 95% lower limit) leads to superior growth of normal lung tissue (assessed indirectly by body weight) at 6 months corrected age as compared to targeting a lower SpO2 (90% lower limit) in children with moderate-severe BPD from 36 weeks PMA and onwards.